Lin Chang

Treatment of gastrointestinal pain remains a significant challenge in the management of many disorders of gut–brain interaction (DGBI). Pharmacologic agents and various behavioral therapies are among the potential therapeutic options for pain‐predominant DGBI such as irritable bowel syndrome, functional dyspepsia, functional heartburn, and centrally mediated abdominal pain syndrome. In the retrospective study published in this journal, Luo et al. examine the use of prescription pain medications from a global perspective among patients with DGBI using the Rome Foundation Global Epidemiology Study. This review article provides an overview of usage patterns of various pharmacologic pain management agents (opioids, central neuromodulators, antispasmodics, and other peripherally acting agents) and non‐pharmacologic therapies in the context of clinical practice recommendations on the management of DGBI pain.